GSK Challenges Pfizer Over RSV Vaccine Patents: A Battle for Innovation and Intellectual Property

In a recent legal showdown, pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer have become embroiled in a legal dispute over the rights to respiratory syncytial virus (RSV) vaccine patents in the United States. The case underscores the critical role of intellectual property protection in fostering innovation within the research-based pharmaceutical industry.

The crux of the matter lies in Pfizer's Abrysvo, a vaccine designed to combat RSV, a frequently infectious virus that typically causes mild cold-like symptoms. While most individuals recover within a short period of time, the elderly are particularly vulnerable to severe illness. The Food and Drug Administration (FDA) approved GSK's Arexvy, the first RSV vaccine to receive approval on a global scale, in May. Pfizer's vaccine followed quickly.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

GSK's lawsuit contends that Pfizer's Abrysvo infringes upon four of its patented technologies integral to Arexvy's development. A GSK spokeswoman emphasized that "intellectual property protections are the foundation of research-based companies’ ability to drive innovation" and asserted that Arexvy's launch should have been unmarried by litigation.

Central to GSK's argument is the timeline of both companies' RSV programs. GSK asserts that it embarked on its RSV research seven years ahead of Pfizer, in 2013. Pfizer, however, is alleged to have had knowledge of GSK's patented technology until 2019, when it contested European patents. The complaint suggests that Pfizer knowingly incorporated GSK's claimed interventions into Abrysvo without authorization.

Following the legal dispute, GSK has filed a claim for damages and an injunction prohibiting the sale of Pfizer's Abrysvo in the US. Despite this courtroom confrontation, Pfizer's vaccine remains accessible for preventing RSV in newborns through active vaccination of pregnant women.

Analysts predict a promising future for the RSV vaccine market, estimating its value to range between $5 billion and $10 billion by 2030. In addition to GSK and Pfizer, other pharmaceutical players such as Moderna and Bavarian Nordic are also actively developing RSV candidates, indicating substantial interest and investment in combating this ailment.

The dispute between GSK and Pfizer serves as a reminder of the pivotal role that intellectual property protection plays in fostering a climate of innovation within the pharmaceutical sector. As these companies vie for supremacy in the burgeoning RSV vaccine market, the outcome of this legal clash will likely have far-reaching implications for the industry's approach to intellectual property rights, future innovation, and ultimately, the health and well-being of vulnerable populations.